NEW YORK, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR T) technology and gene therapies for rare diseases, today announced the appointment of Martina A. Sersch, M.D., Ph.D., as Chief Medical Officer (“CMO”). Dr. Sersch will oversee the clinical development of Mustang’s pipeline in CAR T technology and gene therapies.
Manuel Litchman, M.D., President and Chief Executive Officer of Mustang, said, “We are delighted to welcome Martina to the Mustang leadership team. Her extensive global immuno-oncology drug development expertise and vast array of experience in bringing innovative oncology products to market will help guide Mustang’s clinical development efforts and regulatory strategies in an exciting time of growth for the company.”
Dr. Sersch is an experienced drug developer and physician with specialty training in oncology, infectious and tropical diseases. She has more than 17 years of experience in early- and late-stage clinical development in academia and industry. Prior to joining Mustang, Dr. Sersch served as executive director at Amgen, where she successfully led supplemental Biologics License Application filings in the area of hematology, as well as indication strategies for early- and late-stage compounds in hematology. Prior to Amgen, Dr. Sersch held positions of increasing responsibility on regional and global levels in oncology drug development, including novel immuno-oncology drugs at IRAD Oncology, Genentech, Roche and Pfizer. At Roche, Dr. Sersch was instrumental in the biologics strategy, where she led initiatives globally and regionally with a specific focus in Asia Pacific and China, including supporting the development of regional guidelines for drug development. Dr. Sersch obtained her medical and graduate degrees from Heidelberg University in Germany and subsequently trained in England, South Africa and the United States.
Dr. Sersch said, “I am thrilled to join Mustang to help advance the development of its CAR T and CRISPR/Cas9-enhanced CAR T therapies across multiple cancers, as well as its lentiviral gene therapy for XSCID. I look forward to working with the Mustang team as we strive to deliver promising new treatment options for patients and their families in areas of unmet medical need.”
About Mustang Bio
Mustang Bio, Inc. (“Mustang”), is a clinical‐stage biopharmaceutical company focused on the development and commercialization of a broad range of proprietary chimeric antigen receptor engineered T cell (CAR T) immunotherapies and gene therapies in areas of unmet need. Mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, to fund research and development, and to outlicense or bring the technologies to market. Mustang has partnered with top medical institutions to advance the development of CAR T and CRISPR/Cas9-enhanced CAR T therapies across multiple cancers, as well as a lentiviral gene therapy for XSCID. Mustang is registered under the Securities Exchange Act of 1934, as amended, and files periodic reports with the U.S. Securities and Exchange Commission. For more information, visit www.mustangbio.com.
This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.
Mustang Bio, Inc.
Investor Relations Contact:
Managing Director, LifeSci Advisors, LLC
Media Relations Contact: